Nestle Completes Purchase of Aimmune Therapeutics Shares; Plans Merger With Subsidiary
13 Octobre 2020 - 8:15AM
Dow Jones News
By Joshua Kirby
Nestle SA said Tuesday that it has bought a number of shares in
Aimmune Therapeutics Inc., taking its holding in the pharmaceutical
company to 84%.
The Swiss food-and-beverage conglomerate said its wholly-owned
subsidiary SPN MergerSub had purchased around 43.4 million shares
via a tender offer at a price of $34.50 per share. Added to the
shares already owned by Nestle and its subsidiaries, it represents
around 84% of the outstanding shares in Aimmune Therapeutics, the
company said.
SPN MergerSub will be merged with Aimmune Therapeutics, which
will continue as the surviving corporation, Nestle said.
Write to Joshua Kirby at joshua.kirby@dowjones.com
(END) Dow Jones Newswires
October 13, 2020 02:00 ET (06:00 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Aimmune Therapeutics (NASDAQ:AIMT)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Aimmune Therapeutics (NASDAQ:AIMT)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Aimmune Therapeutics Inc (NASDAQ): 0 recent articles
Plus d'articles sur Aimmune Therapeutics Inc